| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC0276 | 5-cltep | HIV-1 integrase inhibitor |
|
| DCC0277 | 5-formylcytosine | Rare base found in mammalian DNA, having functional roles in DNA that go beyond being a demethylation intermediate |
|
| DCC0278 | 5-fu Prodrug 4 | Novel palladium-activated 5-FU prodrug, being completely innocuous to cells and highly resistant to metabolization by primary hepatocytes and liver S9 fractions (the main metabolic route for 5-FU degradation), and rapidly converted into 5-FU in the presen |
|
| DCC0279 | 5-hiaa | Serotonin metabolite, systemically inhibiting RAS/MAPK signaling in different organs of C. elegans |
|
| DCC0280 | 5-ht2c Agonist 58 | Novel selective 5-HT 2C agonist with >300-fold functional selectivity over 5-HT 2B and >70-fold functional selectivity over 5-HT 2A , reducing food intake in an acute rat feeding model |
|
| DCC0281 | 5-ht3 Antagonist-4i Featured | 5-HT3 antagonist 4 is a 5-HT3 receptor (5HT3R) antagonist. 5-HT3 antagonist 4 prevents diabetes-induced depressive phenotypes in mice. |
|
| DCC0282 | 5-ht7r Antagonist 2c | Novel potent and selective G protein-biased 5-HT 7 R Antagonist, significantly reducing self-grooming duration time to the level of wild-type mice |
|
| DCC0283 | 5-hydroxydantrolene | Metabolite of dantrolene |
|
| DCC0284 | 5'-hydroxydatiscetin | Morin isomer, antioxidant |
|
| DCC0285 | 5-hydroxydiclofenac | Active metabolite of diclofenac, targeting COX and CaMKIIα hub domain |
|
| DCC0286 | 5-mca-nat | Melatonin analogue, selectively binding on MT3 subsites |
|
| DCC0287 | 5-methoxyleoligin | Natural proangiogenic agent, downregulating the cellular uptake of all- trans-retinoic acid (atRA) under hypoxia |
|
| DCC0288 | 5-methyl-ds2 | Novel potent δ-selective allosteric modulator, displayed at least 60-fold selectivity for α4β1δ over α4β1γ2 receptor subtypes, Ki(α4β1δ |
|
| DCC0289 | 5-mpep | Neutral allosteric site ligand of the metabotropic glutamate receptor subtype 5 (mGlu5), blocking the effects of both the allosteric antagonist MPEP and potentiator CDPPB |
|
| DCC0290 | 5n-bicalutamide | Novel highly potent nonsteroidal antiandrogen (NSAA) |
|
| DCC0291 | 5-oh-hxmf | Inducer of neurite outgrowth via cAMP/PKA/CREB pathway in PC12 cells |
|
| DCC0292 | 5-oh-phip | PhIP metabolite |
|
| DCC0293 | 5'-o-methyl-3-hydroxyflemingin A | Natural inhibitor of hedgehog (Hh) signal transduction, diminishing characteristics of cancer stem cells, leading to decreasing production of the Hh target proteins BCL2, PTCH1, and BMI1 |
|
| DCC0294 | 5'-o-tritylthymidine | Blocker of the formation of the FAK/Mdm-2 complex; subsequently, activating p53 and caspase-8 and leading to increase detachment and apoptosis in breast and colon cancers |
|
| DCC0295 | 5sglcnhex | Novel O-GlcNAc transferase (OGT) inhibitor, inducing dose- and time-dependent decreases in O-GlcNAc levels |
|
| DCC0296 | 5'-ß-l-asp-fudr | Novel FUdR prodrug. possessing a better tumor inhibition rate and a better metabolic stability than FUdR through a ATB0, -mediated prodrug approach |
|
| DCC0297 | 6"-o-acetyldaidzin | Metabolite of soy isoflavone; Antioxidant |
|
| DCC0298 | 6"-o-acetylgenistin | Metabolite of soy isoflavones |
|
| DCC0299 | 6"-o-malonyldaidzin | Metabolite of soy isoflavones |
|
| DCC0300 | 6,6''-biapigenin | Potent and selective nociceptin opioid receptor (NOP) agonist |
|
| DCC0301 | 6,7,3',4'-tetrahydroxyflavone | Novel potent MtbCoaBC inhibitor (IC50: 0.08 µM) |
|
| DCC0302 | 6,8-diprenyleriodictyol | Antioxidant, inhibiting Cu(2+)-mediated oxidation of human low density lipoprotein (LDL) |
|
| DCC0303 | 65-a11 | Novel methuselah (Mth)-specific antagonist |
|
| DCC0304 | 680sir | Novel fluorescent probe for near-IR live-cell super-resolution imaging |
|
| DCC0305 | 6-alkynyl-fucose | Widely used fucosylation probe, strongly inhibiting fucosylation and GDP-fucose synthetase FX, halting hepatoma invasion |
|
